PI
PLX icon

PFG Investments’s Protalix BioTherapeutics PLX Stock Holding History

PFG Investments’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,730
Closed -$39K – 1078
2024
Q4 		$39K Buy
+20,730
New +$29.3K ﹤0.01% 991

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PFG Investments's PLX Position: Q1 2025 in Review

PFG Investments sold out of Protalix BioTherapeutics (PLX) in Q1 2025, closing a stake of 20,730 shares — an estimated $39K sold.

PFG Investments first reported a position in PLX in Q4 2024 and held it in 1 quarter. The position peaked at $39K in Q4 2024. 63 funds tracked by Wall St. Rank hold PLX as of Q1 2025.

  • PFG Investments reported no remaining Protalix BioTherapeutics position as of Q1 2025 after selling out during the quarter.
  • PFG Investments sold 20,730 Protalix BioTherapeutics shares in Q1 2025, an estimated $39K.
  • PFG Investments first reported a position in Protalix BioTherapeutics in Q4 2024 and held it in 1 quarter.
  • PFG Investments's Protalix BioTherapeutics position peaked at $39K in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2025.

Based on PFG Investments's 13F filing for Q1 2025, filed 22 Apr 2025.